Cerebrolysin
A porcine brain-derived peptide preparation containing neurotrophic factors that mimic the activity of BDNF and NGF, approved in over 40 countries for stroke and dementia.
Also known as: FPF 1070, Porcine brain-derived peptide preparation
Regulatory Status
Classification date: 2024-06-01
Compounding: Not currently available for compounding
Evidence Summary
How It Works
Cerebrolysin is a standardized mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue. Its active peptide fractions mimic the activity of endogenous neurotrophic factors (BDNF, NGF, CNTF), promoting neuronal survival, synaptic plasticity, and neurogenesis. It reduces amyloid-beta aggregation, inhibits GSK-3beta (a kinase implicated in tau hyperphosphorylation), and protects mitochondrial function. It is approved in over 40 countries for stroke recovery, traumatic brain injury, and Alzheimer's disease, but not in the United States.
Common Applications
Safety & Considerations
Generally well tolerated. Side effects include dizziness, headache, and injection-site reactions. Rare reports of agitation, confusion, and seizures at high doses. Must be administered by slow IV infusion. As a biologically derived product, batch-to-batch consistency and immunogenic potential are considerations. Not FDA-approved; available only outside the US and through clinical trials.
Regulatory classifications can change rapidly. The information shown here was last verified on 2024-06-01. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.